We serve Chemical Name:2-(2,4-difluorobenzoyl)-3-(dimethylamino)acrylonitrile CAS:138716-60-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(2,4-difluorobenzoyl)-3-(dimethylamino)acrylonitrile
CAS.NO:138716-60-6
Synonyms:MFCD03453099;2-(2,4-difluorobenzoyl)-3-(dimethylamino)acrylonitrile
Molecular Formula:C12H10F2N2O
Molecular Weight:236.21700
HS Code:2926909090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:411.4ºC at 760mmHg
Density:1.246g/cm3
Index of Refraction:1.527
PSA:44.10000
Exact Mass:236.07600
LogP:2.11658
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD03453099 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(2,4-difluorobenzoyl)-3-(dimethylamino)acrylonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD03453099 Use and application,2-(2,4-difluorobenzoyl)-3-(dimethylamino)acrylonitrile technical grade,usp/ep/jp grade.
Related News: In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers. 2-(2,4-difluorobenzoyl)-3-(dimethylamino)acrylonitrile manufacturer Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. 2-(2,4-difluorobenzoyl)-3-(dimethylamino)acrylonitrile supplier he agency said the drugmaker and Emergent must agree that the FDA can share relevant information about the manufacturing of the doses with regulators where the vaccine is shipped. 2-(2,4-difluorobenzoyl)-3-(dimethylamino)acrylonitrile vendor In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers. 2-(2,4-difluorobenzoyl)-3-(dimethylamino)acrylonitrile factory Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients.
